<span style="color: green;">This label may not be the latest approved by FDA.
</span><span style="color: green;">
</span><span style="color: green;">For current labeling information, please visit https://www.fda.gov/drugsatfda
</span><span style="color: green;">
</span># HIGHLIGHTS OF PRESCRIBING INFORMATION

<span style="color: red;">This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda
</span><span style="color: green;">These highlights do not include all the information needed to use ACETADOTE safely and effectively. See full prescribing information for ACETADOTE.
</span>
<span style="color: red;">These highlights do not include all the information needed to use ACETADOTE safely and effectively. See full prescribing information for examples of osmolarity depending on the type of solution and ACETADOTE concentration.
</span><span style="color: green;"># ACETADOTE (acetylcysteine) injection, for intravenous use
</span>
<span style="color: green;">Initial U.S. Approval: 2004
</span><span style="color: red;"># Recommended Adult and Pediatric Dosage (2.4):
</span><span style="color: red;">
</span><span style="color: red;">ACETADOTE (acetylcysteine) injection, for intravenous use
</span>
- ACETADOTE is for intravenous administration only
- Total dosage of ACETADOTE is 300 mg/kg given intravenously as 3 separate doses and total recommended infusion time for 3 doses is 21 hours
<span style="color: red;">- See Full Prescribing Information for weight-based dosage and weight-based dilution (2.4)
</span>                                                                                    ------
<span style="color: green;">- See Full Prescribing Information for weight-based dosage and weight-based dilution
</span><span style="color: red;">- See Full Prescribing Information for recommendations for continuing ACETADOTE treatment after 21 hours (2.2)
</span>                                                                                                        ------
<span style="color: green;">- See Full Prescribing Information for recommendations for continuing ACETADOTE treatment after 21 hours
</span>
# INDICATIONS AND USAGE

<span style="color: red;">ACETADOTE is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) (1).
</span>                                                                                                                                                                                                                                                        ----------
<span style="color: green;">ACETADOTE is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion.
</span>
# DOSAGE AND ADMINISTRATION

<span style="color: red;"># Pre-Treatment Assessment Following Acute Ingestion (2.1):
</span>                                                    -------
<span style="color: green;"># Pre-Treatment Assessment Following Acute Ingestion
</span>
Obtain a plasma or serum sample to assay for acetaminophen concentration at least 4 hours after ingestion.

- If the time of acetaminophen ingestion is unknown:
<span style="color: green;">- Administer a loading dose of ACETADOTE immediately.
</span><span style="color: green;">- Obtain an acetaminophen concentration to determine need for continued treatment.
</span><span style="color: red;">
</span><span style="color: red;"># DOSAGE FORMS AND STRENGTHS
</span><span style="color: red;">
</span><span style="color: red;">Injection: 6 grams/30 mL (200 mg/mL) in a single-dose vial (3)
</span>
# CONTRAINDICATIONS

<span style="color: red;">Patients with a previous hypersensitivity reaction to acetylcysteine (4)
</span>                                                                    ^^^^
<span style="color: green;">Patients with a previous hypersensitivity reaction to acetylcysteine.
</span>                                                                    ^

# WARNINGS AND PRECAUTIONS

<span style="color: red;">- Hypersensitivity Reactions, Including Hypotension, Wheezing, Shortness of Breath and Bronchospasm: Observe patients during and after the infusion; immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment. ACETADOTE infusion may be carefully restarted after treatment of hypersensitivity has been initiated (5.1).
</span>                                                                                                                                                                                                                                                      ------------------------------------------------------------------------------------------------------------
<span style="color: green;">- Hypersensitivity Reactions, Including Hypotension, Wheezing, Shortness of Breath and Bronchospasm: Observe patients during and after the infusion; immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment.
</span><span style="color: red;">- Fluid Overload: Total volume administered should be reduced for patients weighing less than 40 kg and for those requiring fluid restriction (5.2).
</span>                                                                                                                                             ------
<span style="color: green;">- Fluid Overload: Total volume administered should be reduced for patients weighing less than 40 kg and for those requiring fluid restriction.
</span>
# ADVERSE REACTIONS

<span style="color: red;">Most common adverse reactions (> 2%) are rash, urticaria/facial flushing and pruritus (6.1).
</span>                                -                                                    ------
<span style="color: green;">Most common adverse reactions (>2%) are rash, urticaria/facial flushing and pruritus.
</span>
<span style="color: green;"># NOMOGRAM FOR ESTIMATING POTENTIAL FOR HEPATOTOXICITY FROM ACUTE ACETAMINOPHEN INGESTION
</span><span style="color: red;">To report SUSPECTED ADVERSE REACTIONS, contact Cumberland Pharmaceuticals Inc. at 1-877-484-2700 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
</span><span style="color: red;">
</span><span style="color: red;"># NOMOGRAM for Estimating Potential for Hepatotoxicity from Acute Acetaminophen Ingestion (2.2):
</span>
See Full Prescribing Information for instructions on how to use the nomogram to determine the need for dosing.

<span style="color: red;"># Preparation and Storage of Diluted Solution Prior to Administration (2.3):
</span>                                                                     -------
<span style="color: green;"># Preparation and Storage of Diluted Solution Prior to Administration
</span>
<span style="color: red;">ACETADOTE is hyperosmolar (2600 mOsmol/L), therefore ACETADOTE must be diluted in sterile water for injection, 0.45% sodium chloride injection, or...
</span>                                                                                                                                                  ^^
<span style="color: green;">ACETADOTE is hyperosmolar (2600 mOsmol/L), therefore ACETADOTE must be diluted in sterile water for injection, 0.45% sodium chloride injection, or 5% dextrose in water injection prior to intravenous administration.
</span>                                                                                                                                                  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

<span style="color: red;"># FULL PRESCRIBING INFORMATION: CONTENTS*
</span>                                        -
<span style="color: green;"># FULL PRESCRIBING INFORMATION: CONTENTS
</span>
1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
<span style="color: red;">3. 1. Pre-Treatment Assessment and Testing Following Acute Acetaminophen Ingestion
</span>---
<span style="color: green;">1. Pre-Treatment Assessment and Testing Following Acute Acetaminophen Ingestion
</span>2. Nomogram for Estimating Potential for Hepatotoxicity from Acute Acetaminophen Ingestion and Need for ACETADOTE Treatment
3. Preparation and Storage of ACETADOTE Diluted Solution Prior to Administration
4. Recommended Dosage in Adults and Pediatrics for Acute Acetaminophen Ingestion
5. Recommendations for Repeated Supratherapeutic Acetaminophen Ingestion
<span style="color: red;">
</span><span style="color: red;">DOSAGE FORMS AND STRENGTHS
</span><span style="color: green;">3. DOSAGE FORMS AND STRENGTHS
</span>+++
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
<span style="color: green;">1. Hypersensitivity Reactions
</span><span style="color: green;">2. Fluid Overload
</span>6. ADVERSE REACTIONS
<span style="color: green;">7. USE IN SPECIFIC POPULATIONS
</span><span style="color: green;">1. Pregnancy
</span><span style="color: green;">2. Lactation
</span><span style="color: green;">3. Pediatric Use
</span><span style="color: green;">8. OVERDOSAGE
</span><span style="color: green;">9. DESCRIPTION
</span><span style="color: green;">10. CLINICAL PHARMACOLOGY
</span><span style="color: green;">1. Mechanism of Action
</span><span style="color: green;">2. Pharmacokinetics
</span><span style="color: green;">11. NONCLINICAL TOXICOLOGY
</span><span style="color: green;">1. Carcinogenesis, Mutagenesis, Impairment of Fertility
</span><span style="color: green;">12. CLINICAL STUDIES
</span><span style="color: green;">13. HOW SUPPLIED/STORAGE AND HANDLING
</span><span style="color: green;">14. PATIENT COUNSELING INFORMATION
</span>
<span style="color: red;">*Sections or subsections omitted from the Full Prescribing Information are not listed.
</span><span style="color: green;">Revised: 10/2019
</span>
<span style="color: red;">ACETADOTEÂ® (acetylcysteine) Injection
</span><span style="color: red;">
</span><span style="color: red;">Revised: 1/2017
</span><span style="color: red;">
</span><span style="color: red;">Reference ID: 4044640</span>               ^^^ ^^
<span style="color: green;">Reference ID: 4513653</span>               ^^^ ^^
